AU2008252014B2 - Protein assay - Google Patents
Protein assay Download PDFInfo
- Publication number
- AU2008252014B2 AU2008252014B2 AU2008252014A AU2008252014A AU2008252014B2 AU 2008252014 B2 AU2008252014 B2 AU 2008252014B2 AU 2008252014 A AU2008252014 A AU 2008252014A AU 2008252014 A AU2008252014 A AU 2008252014A AU 2008252014 B2 AU2008252014 B2 AU 2008252014B2
- Authority
- AU
- Australia
- Prior art keywords
- reactive component
- thrombin
- solution
- fibrinogen
- admixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000002731 protein assay Methods 0.000 title description 2
- 108090000190 Thrombin Proteins 0.000 claims abstract description 116
- 229960004072 thrombin Drugs 0.000 claims abstract description 116
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 79
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 79
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 79
- 230000000694 effects Effects 0.000 claims abstract description 59
- 238000000034 method Methods 0.000 claims abstract description 39
- 239000000243 solution Substances 0.000 claims description 76
- 230000002401 inhibitory effect Effects 0.000 claims description 37
- 230000035602 clotting Effects 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 14
- 239000000758 substrate Substances 0.000 claims description 14
- 206010053567 Coagulopathies Diseases 0.000 claims description 10
- 229940122388 Thrombin inhibitor Drugs 0.000 claims description 10
- 239000003868 thrombin inhibitor Substances 0.000 claims description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 9
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 8
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims description 8
- 230000015271 coagulation Effects 0.000 claims description 8
- 238000005345 coagulation Methods 0.000 claims description 8
- 239000003055 low molecular weight heparin Substances 0.000 claims description 8
- 229940127215 low-molecular weight heparin Drugs 0.000 claims description 8
- 239000012670 alkaline solution Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 claims description 6
- INEWUCPYEUEQTN-UHFFFAOYSA-N 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CNC1CCCCC1 INEWUCPYEUEQTN-UHFFFAOYSA-N 0.000 claims description 6
- NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 claims description 6
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 claims description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 6
- MKWKNSIESPFAQN-UHFFFAOYSA-N N-cyclohexyl-2-aminoethanesulfonic acid Chemical compound OS(=O)(=O)CCNC1CCCCC1 MKWKNSIESPFAQN-UHFFFAOYSA-N 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- 108010055460 bivalirudin Proteins 0.000 claims description 6
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 6
- 239000010452 phosphate Substances 0.000 claims description 6
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 claims description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 5
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 claims description 5
- BISKEOIROPAOGY-RXQQAGQTSA-N (2s)-n-[(2s)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(2r)-2-(methylamino)-3-phenylpropanoyl]pyrrolidine-2-carboxamide;sulfuric acid Chemical compound OS(O)(=O)=O.C([C@@H](NC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C=O)C1=CC=CC=C1 BISKEOIROPAOGY-RXQQAGQTSA-N 0.000 claims description 4
- CDPROXZBMHOBTQ-SJORKVTESA-N 2-[[(2r)-3-cyclohexyl-1-[(2s)-2-[3-(diaminomethylideneamino)propylcarbamoyl]piperidin-1-yl]-1-oxopropan-2-yl]amino]acetic acid Chemical compound NC(N)=NCCCNC(=O)[C@@H]1CCCCN1C(=O)[C@H](NCC(O)=O)CC1CCCCC1 CDPROXZBMHOBTQ-SJORKVTESA-N 0.000 claims description 4
- 101000772006 Bombus ignitus Venom serine protease Bi-VSP Proteins 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- 239000004019 antithrombin Substances 0.000 claims description 4
- 239000007900 aqueous suspension Substances 0.000 claims description 4
- 229960003856 argatroban Drugs 0.000 claims description 4
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 claims description 4
- 229960001500 bivalirudin Drugs 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 230000002596 correlated effect Effects 0.000 claims description 4
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 claims description 4
- 229960003850 dabigatran Drugs 0.000 claims description 4
- XYWBJDRHGNULKG-OUMQNGNKSA-N desirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 XYWBJDRHGNULKG-OUMQNGNKSA-N 0.000 claims description 4
- 229960000296 desirudin Drugs 0.000 claims description 4
- 108010073652 desirudin Proteins 0.000 claims description 4
- 229950009814 efegatran Drugs 0.000 claims description 4
- 108010078659 efegatran Proteins 0.000 claims description 4
- 229960002897 heparin Drugs 0.000 claims description 4
- 229920000669 heparin Polymers 0.000 claims description 4
- 229950003291 inogatran Drugs 0.000 claims description 4
- OTQCKZUSUGYWBD-BRHMIFOHSA-N lepirudin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 OTQCKZUSUGYWBD-BRHMIFOHSA-N 0.000 claims description 4
- 229960004408 lepirudin Drugs 0.000 claims description 4
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 claims description 4
- 229960002137 melagatran Drugs 0.000 claims description 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000008000 CHES buffer Substances 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- 239000007995 HEPES buffer Substances 0.000 claims description 3
- 239000007983 Tris buffer Substances 0.000 claims description 3
- 229960002319 barbital Drugs 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
- 108010001779 Ancrod Proteins 0.000 claims description 2
- 108010027612 Batroxobin Proteins 0.000 claims description 2
- PJWWRFATQTVXHA-UHFFFAOYSA-N Cyclohexylaminopropanesulfonic acid Chemical compound OS(=O)(=O)CCCNC1CCCCC1 PJWWRFATQTVXHA-UHFFFAOYSA-N 0.000 claims description 2
- 229960004233 ancrod Drugs 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 229960002210 batroxobin Drugs 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims 2
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 claims 2
- 229960001318 fondaparinux Drugs 0.000 claims 2
- NABMTTWARSHKGC-UHFFFAOYSA-N 2-[1-(2-sulfoethyl)piperazin-2-yl]ethanesulfonic acid Chemical compound OS(=O)(=O)CCC1CNCCN1CCS(O)(=O)=O NABMTTWARSHKGC-UHFFFAOYSA-N 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 1
- 238000004848 nephelometry Methods 0.000 claims 1
- 238000004879 turbidimetry Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 abstract description 17
- 102000004169 proteins and genes Human genes 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 26
- 230000002779 inactivation Effects 0.000 description 14
- 102000009123 Fibrin Human genes 0.000 description 12
- 108010073385 Fibrin Proteins 0.000 description 12
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 12
- 229950003499 fibrin Drugs 0.000 description 12
- 230000000887 hydrating effect Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000036571 hydration Effects 0.000 description 4
- 238000006703 hydration reaction Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- FXMGSXNQELBPMX-UHFFFAOYSA-N 5-methylchromen-2-one Chemical compound O1C(=O)C=CC2=C1C=CC=C2C FXMGSXNQELBPMX-UHFFFAOYSA-N 0.000 description 2
- 239000007990 PIPES buffer Substances 0.000 description 2
- 229940003354 angiomax Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 239000012035 limiting reagent Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- NOPJRYAFUXTDLX-UHFFFAOYSA-N 1,1,1,2,2,3,3-heptafluoro-3-methoxypropane Chemical compound COC(F)(F)C(F)(F)C(F)(F)F NOPJRYAFUXTDLX-UHFFFAOYSA-N 0.000 description 1
- QKAGYSDHEJITFV-UHFFFAOYSA-N 1,1,1,2,2,3,4,5,5,5-decafluoro-3-methoxy-4-(trifluoromethyl)pentane Chemical compound FC(F)(F)C(F)(F)C(F)(OC)C(F)(C(F)(F)F)C(F)(F)F QKAGYSDHEJITFV-UHFFFAOYSA-N 0.000 description 1
- 241000271511 Bothrops atrox Species 0.000 description 1
- 241000271064 Calloselasma rhodostoma Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- -1 HFE-7000 Chemical class 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- NFIKTSWJXJTUBZ-ZEQRLZLVSA-N benzyl n-[2-[(2s)-2-[[(2s)-5-(diaminomethylideneamino)-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]carbamate Chemical compound C([C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC2=CC=3OC(=O)C=C(C=3C=C2)C)CCN1C(=O)CNC(=O)OCC1=CC=CC=C1 NFIKTSWJXJTUBZ-ZEQRLZLVSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- VBEGHXKAFSLLGE-UHFFFAOYSA-N n-phenylnitramide Chemical compound [O-][N+](=O)NC1=CC=CC=C1 VBEGHXKAFSLLGE-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000006965 reversible inhibition Effects 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002345 thrombinlike Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2008/064514 WO2009142638A1 (en) | 2008-05-22 | 2008-05-22 | Protein assay |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2008252014A1 AU2008252014A1 (en) | 2009-12-10 |
| AU2008252014B2 true AU2008252014B2 (en) | 2014-06-05 |
Family
ID=40329388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008252014A Ceased AU2008252014B2 (en) | 2008-05-22 | 2008-05-22 | Protein assay |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9213035B2 (pt) |
| EP (1) | EP2124063B1 (pt) |
| JP (1) | JP5539332B2 (pt) |
| KR (1) | KR101511071B1 (pt) |
| CN (1) | CN101680905B (pt) |
| AU (1) | AU2008252014B2 (pt) |
| BR (1) | BRPI0803089A2 (pt) |
| CA (1) | CA2645937C (pt) |
| IL (1) | IL194940A (pt) |
| TW (1) | TWI443193B (pt) |
| WO (1) | WO2009142638A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5539332B2 (ja) * | 2008-05-22 | 2014-07-02 | エシコン・インコーポレイテッド | タンパク質アッセイ |
| US20120294767A1 (en) * | 2011-05-19 | 2012-11-22 | Hemosonics Llc | Portable hemostasis analyzer |
| US8900822B2 (en) * | 2011-11-21 | 2014-12-02 | Ethicon, Inc. | Fibrinogen assay |
| CN103604766A (zh) * | 2013-11-25 | 2014-02-26 | 牡丹江友搏药业股份有限公司 | 一种疏血通注射液的生物学质控方法 |
| CN104965017B (zh) * | 2015-06-17 | 2017-06-16 | 广西师范学院 | 水蛭素抗凝血酶活性的测定方法 |
| CN111684076A (zh) * | 2018-01-25 | 2020-09-18 | 帝斯曼知识产权资产管理有限公司 | 纤维蛋白原测试 |
| JP7191613B2 (ja) * | 2018-09-26 | 2022-12-19 | キヤノンメディカルシステムズ株式会社 | 血液凝固分析装置 |
| IL263679A (en) * | 2018-12-12 | 2019-03-31 | Omrix Biopharmaceuticals Ltd | Kits, methods, and ingredients for preventing tissue adhesion |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0570354A1 (de) * | 1992-05-15 | 1993-11-18 | IMMUNO Aktiengesellschaft | Verfahren zur Bestimmung von Fibrinogen |
| US5292664A (en) * | 1991-10-14 | 1994-03-08 | Behringwerke Aktiengesellschaft | Functional test and reagent for determining fibrinogen |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1161878A1 (ru) | 1982-07-21 | 1985-06-15 | Белорусский научно-исследовательский институт переливания крови | Способ определени активности тромбина |
| DE3330699A1 (de) | 1983-08-25 | 1985-03-07 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur gleichzeitigen bestimmung von fibrinogen und fibrinogen-spaltprodukten im plasma |
| US5110727A (en) * | 1987-04-03 | 1992-05-05 | Cardiovascular Diagnostics, Inc. | Method for performing coagulation assays accurately, rapidly and simply, using dry chemical reagents and paramagnetic particles |
| JP2811799B2 (ja) | 1989-09-11 | 1998-10-15 | 三菱化学株式会社 | プロトロンビンの測定方法 |
| US6060451A (en) | 1990-06-15 | 2000-05-09 | The National Research Council Of Canada | Thrombin inhibitors based on the amino acid sequence of hirudin |
| SU1767425A1 (ru) | 1990-07-31 | 1992-10-07 | Научно-Исследовательский Институт Трансплантологии И Искусственных Органов | Способ определени функциональной полноценности фибриногена |
| JPH06209794A (ja) * | 1993-01-19 | 1994-08-02 | Tokuyama Soda Co Ltd | フィブリノゲンの定量方法 |
| EP0587398B1 (en) * | 1992-09-09 | 1998-01-14 | Tokuyama Corporation | Method of assaying fibrinogen, dry reagent therefor, and process for the preparation thereof |
| JP2994557B2 (ja) | 1994-09-02 | 1999-12-27 | 株式会社アズウェル | フィブリノゲン測定方法およびその測定試薬 |
| US5589571A (en) | 1994-10-28 | 1996-12-31 | Cor Therapeutics, Inc. | Process for production of inhibited forms of activated blood factors |
| JPH09266798A (ja) * | 1996-03-29 | 1997-10-14 | Tokuyama Corp | トロンビン活性の測定法および凝集試薬 |
| JPH11160321A (ja) * | 1997-12-02 | 1999-06-18 | A & T:Kk | 血液凝固検査試薬および血液凝固能の測定方法 |
| US6448024B1 (en) | 2000-10-03 | 2002-09-10 | Roche Diagnostics Corporation | Method, reagent, cartridge, and device for determining fibrinogen |
| US7109163B2 (en) * | 2004-01-30 | 2006-09-19 | Ethicon, Inc. | Hemostatic compositions and devices |
| DE102005008066A1 (de) * | 2005-02-22 | 2006-08-24 | Haemosys Gmbh | Verfahren zur Bestimmung der Gesamtgerinnungsaktivität einer Blut- oder Plasmaprobe |
| CN1763219A (zh) * | 2005-10-11 | 2006-04-26 | 广西医科大学 | 检测凝血酶、类凝血酶及凝血酶抑制剂的纤维蛋白原平板法 |
| US9096839B2 (en) | 2006-04-26 | 2015-08-04 | Arteriocyte Medical Systems, Inc. | Compositions and methods of preparation thereof |
| US8133696B2 (en) * | 2006-06-06 | 2012-03-13 | Thrombinoscope B.V. | Method for determining thrombin activity |
| CN101059521B (zh) * | 2007-05-30 | 2011-06-29 | 保定天岳生物工程有限公司 | 一种无需稀释血浆样本测定纤维蛋白原含量的试剂及其测定方法 |
| JP5539332B2 (ja) * | 2008-05-22 | 2014-07-02 | エシコン・インコーポレイテッド | タンパク質アッセイ |
-
2008
- 2008-05-22 JP JP2011510473A patent/JP5539332B2/ja not_active Expired - Fee Related
- 2008-05-22 US US12/298,814 patent/US9213035B2/en active Active
- 2008-05-22 AU AU2008252014A patent/AU2008252014B2/en not_active Ceased
- 2008-05-22 WO PCT/US2008/064514 patent/WO2009142638A1/en active Application Filing
- 2008-05-22 CN CN2008800001990A patent/CN101680905B/zh not_active Expired - Fee Related
- 2008-05-22 KR KR1020087029100A patent/KR101511071B1/ko active IP Right Grant
- 2008-05-22 BR BRPI0803089-8A patent/BRPI0803089A2/pt not_active Application Discontinuation
- 2008-05-22 CA CA2645937A patent/CA2645937C/en active Active
- 2008-10-27 IL IL194940A patent/IL194940A/en active IP Right Grant
- 2008-10-31 TW TW97141904A patent/TWI443193B/zh not_active IP Right Cessation
-
2009
- 2009-05-21 EP EP20090251374 patent/EP2124063B1/en active Active
-
2015
- 2015-11-03 US US14/930,799 patent/US9896716B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5292664A (en) * | 1991-10-14 | 1994-03-08 | Behringwerke Aktiengesellschaft | Functional test and reagent for determining fibrinogen |
| EP0570354A1 (de) * | 1992-05-15 | 1993-11-18 | IMMUNO Aktiengesellschaft | Verfahren zur Bestimmung von Fibrinogen |
Also Published As
| Publication number | Publication date |
|---|---|
| TW200948968A (en) | 2009-12-01 |
| EP2124063B1 (en) | 2012-06-20 |
| US20110053193A1 (en) | 2011-03-03 |
| CA2645937A1 (en) | 2009-11-22 |
| BRPI0803089A2 (pt) | 2011-08-30 |
| AU2008252014A1 (en) | 2009-12-10 |
| IL194940A (en) | 2014-08-31 |
| CA2645937C (en) | 2019-08-27 |
| US9213035B2 (en) | 2015-12-15 |
| US9896716B2 (en) | 2018-02-20 |
| CN101680905A (zh) | 2010-03-24 |
| JP2011523461A (ja) | 2011-08-11 |
| JP5539332B2 (ja) | 2014-07-02 |
| WO2009142638A1 (en) | 2009-11-26 |
| KR20110010842A (ko) | 2011-02-08 |
| KR101511071B1 (ko) | 2015-04-10 |
| IL194940A0 (en) | 2009-12-24 |
| CN101680905B (zh) | 2013-11-27 |
| EP2124063A1 (en) | 2009-11-25 |
| US20160053299A1 (en) | 2016-02-25 |
| TWI443193B (zh) | 2014-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9896716B2 (en) | Protein assay | |
| Ammollo et al. | Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin‐activatable fibrinolysis inhibitor | |
| KR20090023369A (ko) | Ｄ-다이머 및 가용성 피브린 수준 측정에 의한 혈전색전성 정맥 질환의 검출 | |
| JPH0368680B2 (pt) | ||
| US9902952B2 (en) | Euglobulin-based method for determining the biological activity of defibrotide | |
| US8293493B2 (en) | Thrombin generation determination method | |
| CN102798632A (zh) | 一种检测巴曲酶活性的方法 | |
| CA2484554A1 (en) | Diagnostic test for determining the concentration of transient proteolytic activity in composite biological media | |
| RU2462721C2 (ru) | Способ определения активности и функциональности тромбина и фибриногена | |
| DK163189B (da) | Fremgangsmaade og reagens til bestemmelse af plasmas fibrinolytiske tilstand | |
| JP2021511486A (ja) | フィブリノーゲン検査 | |
| WO2001023536A1 (fr) | Stabilisation de la thrombine et compositions | |
| CN114736948B (zh) | 一种α2-抗纤溶酶活性测定试剂盒 | |
| CN109709292A (zh) | 一种肝素检测试剂盒及其应用 | |
| CN114703252A (zh) | 一种用于检测血浆中水蛭素、比伐卢定、达比加群含量的试剂盒 | |
| CN114814245A (zh) | 一种基于发色底物法的蛋白c活性测定试剂盒 | |
| JP2002537820A5 (pt) | ||
| CN115586179A (zh) | 一种用于抗凝血酶ⅲ活性测定的试剂盒及其应用 | |
| JPH0353898A (ja) | 体液中の抗トロンビン３を測定する方法及び試薬 | |
| JP6174367B2 (ja) | トロンビン含有試薬及び測定方法 | |
| Ban et al. | A point-of-care microfluidic channel-based device for rapid and direct detection of fibrinogen in whole blood | |
| JP3554750B2 (ja) | 尿中白血球を検出するための試験紙の品質管理および／または精度管理用組成物、並びに品質管理方法および／または精度管理方法 | |
| JP2548349B2 (ja) | タンパク質加水分解で活性な成分の測定 | |
| CN110423795A (zh) | 一种凝血酶抑制活性的测定方法 | |
| RU2189590C2 (ru) | Способ определения плазминогена |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |